The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
about
Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestationsTargeting the molecular and cellular interactions of the bone marrow niche in immunologic diseaseNeutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrowA phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforChromothriptic cure of WHIM syndrome.IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cellsFilamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptorsWHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantationNeutrophil reverse migration becomes transparent with zebrafish.Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndromeDescription and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia RegistryNeutropenia in primary immunodeficiencyG-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Genetics on a WHIM.Defects of leukocyte migration in primary immunodeficiencies.How we diagnose and treat neutropenia in adults.Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.Is the post-transplantation treatment with AMD beneficial?Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders.Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.
P2860
Q26830870-E5676B3C-6089-4C19-912C-8AB5267A51A4Q26865498-B7223A32-947E-4916-8338-D2F51DB5F579Q30552565-01481259-5C10-4903-8064-C79AAEB58247Q34403975-78A14994-2B96-42FB-98FC-F857B4A0D68AQ35085186-9CFCC53E-43FA-428B-A07F-F7094AFECE5DQ35126751-64CE6CEF-07CC-42A1-A4AC-CD952271C042Q35140322-D2ADEB47-AE29-4865-947A-C5F4A2C722ECQ36079791-6DCCC387-9842-44B6-BCDA-6BBF2027C48EQ36106592-17E7883D-2AA3-46A6-A9E9-0C7DF9B23A9EQ36107308-8F57F80B-5986-4692-96E6-42758C032A86Q36280139-2EFD8D69-36F3-424D-9C0D-0750D5D0D0EFQ36649222-C327FD58-E775-4E51-BDDC-6D7A749FF97DQ37210757-C0DB9F95-5204-4673-AF68-E86A6AC0F5E8Q37272113-C8035F12-4CC3-46B5-895C-B73A0110CA2EQ37432097-A0D2189D-D843-424F-BFFE-915142CA350BQ37653020-863A93A4-34F6-4D56-BA81-7D9D0B0C8345Q38102968-4E646AFF-AEF2-4440-91B3-8CD2184F72ACQ38700289-4D2B6C7D-D975-4D24-AFD6-48555EC1D54BQ39166973-D6330B27-215E-430C-845D-68B48F994C76Q39174058-66179558-669C-484F-A938-01419557FF99Q42139478-2D543D89-B184-4E12-9556-5702571DE35EQ47147843-BA920E34-9304-4E36-96F7-1AB38BB6FC10Q48624133-857CE97F-7338-41EE-B7DA-9392E1176020Q49343068-66B7B5F7-A4E1-4F51-B062-EAB0393A6C60Q49606275-627723F2-64EB-48B3-B9F6-9782AF8161F1Q53061634-B7910AD4-142B-48EF-9152-58E6A46B017DQ54223980-939970B7-8B18-4FAA-A839-8119C22338F7
P2860
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@ast
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@en
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@nl
type
label
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@ast
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@en
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@nl
prefLabel
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@ast
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@en
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@nl
P2093
P2860
P1433
P1476
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
@en
P2093
Andrew Aprikyan
Audrey Anna Bolyard
Brent Wood
David C Dale
Ernest C Westrup
Frank J Hsu
Merideth L Kelley
Vahagn Makaryan
P2860
P304
P356
10.1182/BLOOD-2011-06-360586
P407
P577
2011-08-11T00:00:00Z